scholarly journals Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

2014 ◽  
Vol 10 (4) ◽  
pp. 499-502 ◽  
Author(s):  
Kelly-Anne Phillips ◽  
Geoffrey J Lindeman
Keyword(s):  
Breast Cancer ◽  
Cancer Prevention ◽  
Brca2 Mutation ◽  
Breast Cancer Prevention ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

scholarly journals Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry

2015 ◽  
Vol 151 (3) ◽  
pp. 653-660 ◽  
Author(s):  
Tehillah S. Menes ◽  
Mary Beth Terry ◽  
David Goldgar ◽  
Irene L. Andrulis ◽  
Julia A. Knight ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cumulative Incidence ◽  
Primary Breast Cancer ◽  
Brca2 Mutation ◽  
Second Primary ◽  
Brca1 And Brca2 ◽  
Breast Cancer Family ◽  
Cancer Family ◽  
Mutation Carriers

scholarly journals The frequency and outcome of breast cancer risk-reducing surgery in finnish BRCA1 and BRCA2 mutation carriers

2013 ◽  
Vol 103 (1) ◽  
pp. 34-40 ◽  
Author(s):  
L. Koskenvuo ◽  
C. Svarvar ◽  
S. Suominen ◽  
K. Aittomäki ◽  
T. Jahkola
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Brca2 Mutation ◽  
Brca1 And Brca2 ◽  
Mutation Carriers ◽  
Risk Reducing

The CYP17A1 −34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers

2010 ◽  
Vol 126 (2) ◽  
pp. 521-527 ◽  
Author(s):  
Bella Kaufman ◽  
Yael Laitman ◽  
Elad Ziv ◽  
Ute Hamann ◽  
Diana Torres ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Brca2 Mutation ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

scholarly journals Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

2011 ◽  
Vol 104 (9) ◽  
pp. 1384-1392 ◽  
Author(s):  
K Metcalfe ◽  
S Gershman ◽  
H T Lynch ◽  
P Ghadirian ◽  
N Tung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contralateral Breast Cancer ◽  
Brca2 Mutation ◽  
Contralateral Breast ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers

2009 ◽  
Vol 1 (3) ◽  
pp. 139-147
Author(s):  
Jane C. Figueiredo ◽  
Robert W. Haile ◽  
Jonine L. Bernstein
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Oral Contraceptives ◽  
Brca2 Mutation ◽  
Brca1 And Brca2 ◽  
Mutation Carriers

scholarly journals P2: SNP ANALYSIS IN BRCA POSITIVE AND BRCA NEGATIVE SUBJECTS WITH AND WITHOUT BREAST CANCER (BRCA) REVEAL CENTRAL ROLE OF ALK SNPS AND TGFBETA SUPERFAMILY IN MALIGNANT TRANSFORMATION

2016 ◽  
Vol 64 (3) ◽  
pp. 817.3-818
Author(s):  
I Shapira ◽  
R Huffman ◽  
E Neculiseanu ◽  
A Banavali ◽  
K Guddati ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Transforming Growth Factor Beta ◽  
Survival Data ◽  
Molecular Mechanisms ◽  
Transforming Growth Factor ◽  
Brca2 Mutation ◽  
Snp Analysis ◽  
Brca1 And Brca2 ◽  
Brca Mutations ◽  
Mutation Carriers

Purpose of StudyOver 240,000 individuals are diagnosed with breast cancer each year in the USA. Outcomes depend on DNA deregulations in tumors. Carriers of deleterious BRCA1 and BRCA2 mutations are predisposed to 30 fold higher lifetime risks of breast and ovarian cancer.Aims:1. To check for differences in SNPs of genomic DNA obtained in BRCA+/− with and without BrCa.2. Analyze correlates of molecular mechanisms occurring in BRCA mutant patients.Methods UsedWe analyzed 94 subjects (41 BRCA positive) with or without BrCa to detect SNPs whose expression is significantly differentially expressed between breast cancer and controls. DNA samples were extracted from PBMCs. Samples were measured for DNA concentration using an Invitrogen QuBit Fluorometer, and diluted to 50 ng/µL.All samples were collected between 2010 and 2014 and survival data was known in all cancer patients. Processed samples were sequenced using an Illumina MiSeq Sequencer with a 300 cycle kit to detect SNPs. Variant Call Files were analyzed in Microsoft Excel using Fisher's Exact Test.Summary of ResultsALK SNPs were commonly found in cancer relative to control. Significant associations of ALK SNPs were seen in BRCA mutation subjects. ALK protein was overexpressed in 47% of BRCA mutations cases, which was significantly higher than in non-BRCA cases. Our results show that the ALK signaling pathway possibly is more common in early onset of breast cancer as seen with BRCA mutations. Coremine analysis showed SNPs identified in cancer were most commonly associated with deregulation of Transforming Growth Factor-Beta Superfamily protein synthesis and binding function.ConclusionsDifferences in the associations of the modifying polymorphisms with BrCarisk for BRCA1 and BRCA2 mutation carriers are likely to reflect differences in the biology of tumor development in these two groups of women at high risk of breast cancer. The identification of modifying polymorphisms could therefore lead to a better understanding of the etiology of tumors in mutation carriers and also to the development of effective and more specific therapies for BrCa in mutation carriers.

Sign in / Sign up

Export Citation Format

Share Document